Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
With
Loyola University
Oregon Health and Science University
The purpose of this study is to determine whether the combination of stereotatic body radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective "bridging therapy" for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient capable of giving informed consent
Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution
Age \> 18 years old
Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
Childs' Class A or B7
Eastern Clinical Oncology Group performance status 0 or 1
You may not be if
Prior radiotherapy to the upper abdomen or radioembolization of the liver
Prior TACE to the target lesion, RFA, or liver transplant
Active GI bleed within 2 weeks of study enrollment
Active GI ulcer disease within 4 weeks of study enrollment
Ascites refractory to medical therapy
Contraindication to receiving radiotherapy or TACE
Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
Women who are pregnant
Participation in another concurrent treatment protocol
Clareo Health | TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
